{"entity":{"id":"nct06010329","kind":"trial","name":"A Study to Evaluate the Efficacy and Safety of Sutetinib Maleate Capsule in Locally Advanced or Metastatic NSCLC","aka":[],"tldr":"A phase 2 trial of Sutetinib Maleate Capsule in non-small-cell lung cancer, run by Teligene US, now recruiting.","summary":"A Study to Evaluate the Efficacy and Safety of Sutetinib Maleate Capsule in Locally Advanced or Metastatic NSCLC is a phase 2 interventional study registered as NCT06010329 by Teligene US, with 66 participants planned, started 2023-12-27 and due to reach its primary completion in 2027-12. Interventions recorded: Sutetinib Maleate Capsule.","status":"recruiting","asOf":"2026-09-16","links":[{"label":"ClinicalTrials.gov NCT06010329","url":"https://clinicaltrials.gov/study/NCT06010329"}],"tags":["pipeline","ctgov-ingest"],"related":[],"cancers":["nsclc","egfr-mutant-nsclc"],"sections":[],"technologies":[],"targets":["egfr"],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"nct":"NCT06010329","phase":"2","setting":"A Multicenter, Open-label, Phase 2 Study to Evaluate the Efficacy and Safety of Sutetinib Maleate Capsule in Locally Advanced or Metastatic NSCLC (Uncommon EGFR Mutations Only)","sponsor":"Teligene US","started":"2023-12-27","startedType":"actual","enrolled":66,"enrolledBasis":"registry","outcomes":[]},"route":"/trials/nct06010329/","neighbours":{"cancer":[{"id":"egfr-mutant-nsclc","kind":"cancer","name":"EGFR-mutated non-small-cell lung cancer","route":"/cancers/egfr-mutant-nsclc/"},{"id":"nsclc","kind":"cancer","name":"Non-small-cell lung cancer","route":"/cancers/nsclc/"}],"target":[{"id":"egfr","kind":"target","name":"EGFR","route":"/targets/egfr/"}]}}